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Abstract
Background: People suffering different types of stroke have differing demographic characteristics and survival. 
However, current estimates of disease burden are based on the same underlying assumptions irrespective of stroke 
type. We hypothesized that average Quality Adjusted Life Years (QALYs) lost from stroke would be different for ischemic 
stroke and intracerebral hemorrhage (ICH).
Methods: We used 1 and 5-year data collected from patients with first-ever stroke participating in the North East 
Melbourne Stroke Incidence Study (NEMESIS). We calculated case fatality rates, health-adjusted life expectancy, and 
quality-of-life (QoL) weights specific to each age and gender category. Lifetime 'health loss' for first-ever ischemic 
stroke and ICH surviving 28-days for the 2004 Australian population cohort was then estimated. Multivariable 
uncertainty analyses and sensitivity analyses (SA) were used to assess the impact of varying input parameters e.g. case 
fatality and QoL weights.
Results: Paired QoL data at 1 and 5 years were available for 237 NEMESIS participants. Extrapolating NEMESIS rates, 
31,539 first-ever strokes were expected for Australia in 2004. Average discounted (3%) QALYs lost per first-ever stroke 
were estimated to be 5.09 (SD 0.20; SA 5.49) for ischemic stroke (n = 27,660) and 6.17 (SD 0.26; SA 6.45) for ICH (n = 
4,291; p < 0.001). QALYs lost also differed according to gender for both subtypes (ischemic stroke: males 4.69 SD 0.38, 
females 5.51 SD 0.46; ICH: males 5.82 SD 0.67, females 6.50 SD 0.40).
Discussion: People with ICH incurred greater loss of health over a lifetime than people with ischemic stroke. This is 
explained by greater stroke related case fatality at a younger age, but longer life expectancy with disability after the first 
12 months for people with ICH. Thus, studies of disease burden in stroke should account for these differences between 
subtype and gender. Otherwise, in countries where ICH is more common, health loss for stroke may be 
underestimated. Similar to other studies of this type, the generalisability of the results may be limited. Sensitivity and 
uncertainty analyses were used to provide a plausible range of variation for Australia. In countries with demographic 
and life expectancy characteristics comparable to Australia, our QoL weights may be reasonably applicable.
Background
Worldwide, stroke is a significant contributor to disease
burden. In Australia, stroke is the second leading cause of
death [1]. Of those with first-ever stroke, about 35% die
within 12 months of their stroke [2] and about half of sur-
vivors at 12 months are dependent on others [3]. The cost
of stroke is high, with the present value of lifetime costs
of first-ever stroke in 2004 estimated to cost more than
AUD2 billion (~2% of total annual health expenditure [4])
to the Australian community [5].
In the NEMESIS study, 72.5% of strokes were ischemic
stroke while 14.5% were intracerebral hemorrhage (ICH);
4.3% were subarachnoid hemorrhage and in 8.7% the sub-
type was undetermined [6]. Importantly, these different
types of stroke have different risk factors, treatments and
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outcome. Case-fatality at one year is lower for first-ever
ischemic stroke (reported range from Australian inci-
dence studies 23% to 31%) than for ICH (39% to 50%) and
undetermined stroke (67% to 89%) [6,7]. When assessing
the effect of stroke on society it is important to include
measures of both mortality and morbidity, as stroke
affects both of these outcomes.
Summary measures of population health include
Health Adjusted Life Expectancy (HALE), Disability
Adjusted Life Years (DALYs) and Quality Adjusted Life
Years (QALYs). The HALE value represents the number
of expected years of life equivalent to years lived in full
health adjusted for time spent in poor health based on
current rates of ill-health (e.g. chronic disease) and mor-
tality in a community. The DALY is a health gap measure
and captures the years of life lost (YLL) due to premature
mortality (in this case from stroke) and the years of life
lived with disability (YLD) as a consequence of having
had a stroke. QALYs are based on a similar conceptual
framework (life expectancy plus quality of life [QoL]), but
are often based on different assumptions and methods
[ 8 , 9 ] .  D A L Y S  h a v e  g a i n e d  p r o m i n e n c e  i n  r e c e n t  y e a r s
with the extensive systematic review of burden of disease
[10].
One of the main differences for DALYs and QALYS is
the way health states (i.e. the physical, social and emo-
tional functioning of individuals) [11], such as stroke, are
weighted. Traditionally, QALYs are based on a heath
related QoL weight that is directly derived from
patients or the general population while DALY weights
have more commonly been elicited from expert pan-
els[8,12]. There are both advantages and disadvantages
for each approach. Regardless, the preference weights
derived for both DALYs and QALYs reflect departures
from good health [8,13]. It has been found that stroke
survivors usually assign themselves higher utilities (i.e. a
value that represents the strength of an individual's pref-
erence for a particular health outcome) than do the gen-
eral community or caregivers of stroke survivors [8].
Current estimates of DALYs for stroke in Australia have
used preference weights directly elicited from patients
[14].
QALYs are usually reported as something society will
want to gain, while DALYs are to be avoided. To keep the
concept similar to a DALY, one can instead report the
QALYs lost. This provides a measure of the health gap
experienced by stroke survivors compared to the normal
population and provides an estimate of the health gain
that could be achieved if a stroke was prevented. Such
information is important when making assessments of
the value of various interventions, such as in cost-effec-
tiveness analysis.
Health-related QoL of stroke patients has been well
documented as part of the North East Melbourne Stroke
Incidence Study (NEMESIS). This provided an opportu-
nity to estimate the health loss attributable to stroke
using prospectively elicited QoL data from individual
stroke patients. In NEMESIS a health state classification
questionnaire, the Assessment of Quality of Life (AQoL)
tool [15], was used whereby a utility score (an index of the
strength of a person's preference for a health state where
death is represented as 0.0 and normal health as 1.0)
can be derived. This utility score can be used to provide
the preference weight in estimating health loss. Because
of the recognized differences between the main stroke
subtypes, we hypothesized that average QALYs lost
would be different for ischemic stroke and ICH.
Methods
We developed a 'Lifetable' model, created in Excel
(Microsoft Corporation, 2003), to accommodate a 'life-
time' perspective for an incident cohort of people with
stroke.
Incidence and case-fatality data obtained from NEME-
SIS were applied to Australian population data to esti-
mate the size of the cohort. The NEMESIS data
constitute 'best available' information. Authors of the
2003 Australian BoD study have used NEMESIS data and
have compared representative Australian hospital admis-
sion rates from 1996/1997 with those in NEMESIS
mapped to the relevant statistical local areas[14]. The
ratios of hospital admissions in NEMESIS catchment
areas to those in all of Australia in 1996/97 ranged from
0.9 to 1.3 by age and sex with an overall ratio close to
unity (personal communication, T. Vos March 2010).
Nonetheless, we included point estimates used from
NEMESIS in the sensitivity and uncertainty analyses as
outlined in the Analysis section below. In addition,
because early mortality in ICH is much greater than in
ischemic stroke and would dominate comparisons with
ischemic stroke, estimates of health loss were based on 28
day survivors. Twenty-eight day survivors were catego-
rized into age-groups according to their starting age
(mid-point ages for < 55, 55 to 64, 65 to 74, 75 to 84 and
85+ years) up to age 100. Deaths attributable to stroke
(not 'all cause' mortality) were calculated for day 28, 12
months and then for each year up to 5 years after stroke
using NEMESIS data. Between 5 and 10 years the proba-
bility of dying each year attributable to stroke was main-
tained at the same year 5 probability since no other data
were available. After 10 years, remaining survivors were
assumed to have the same probability of death as the gen-
eral population for that age band and gender. Although
one may argue that mortality risk may not return to that
of the general population, since risk factors in the general
population will have increased over time, and may be at
similar levels to those of the stroke population, we there-Cadilhac et al. Health and Quality of Life Outcomes 2010, 8:49
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fore felt this was a plausible approach given the current
limitations of data.
The QoL weights used to estimate QALYs lost were
derived from the AQoL Mark 1 instrument which has
previously been validated for use in stroke using NEME-
SIS data [16]. We used published 'normal' population val-
ues derived from the AQoL instrument [17] by age band
as a measure of pre-stroke QoL. The QoL (preference)
weight was then calculated as the net difference between
these two scores, and could be described as the utility
loss attributable to stroke. Because it was important
that change in QALYs over time be reported using longi-
tudinal data we used the average of paired utilities
obtained from the same cases at 12 months and 5 years.
In applying these utility values in the 'Lifetable' model a
linear relationship between the 12 month and 5 year val-
ues were assumed. This is because the direction and mag-
nitude of change between the 12 month and 5 year time
points for each age band varied and was usually small
(min 0.006 in < 55 year olds and max 0.12 in 75-84 year
olds). Therefore, a more elaborate approach was consid-
ered unnecessary. After 5 years, we assumed that survi-
vors would have the same utility loss as the 5 year utility
loss in each relevant age band.
To avoid overestimating life expectancy, we used HALE
values calculated for the Australian 2003 BoD study [18]
for life expectancy in our Lifetable model according to
age group. That is, the net difference in health loss due to
stroke was estimated by subtracting the estimated HALE
value for someone without stroke from that estimated for
a person of the same age and gender with stroke to pro-
vide the final QALY loss result. We assumed HALE val-
ues for the 2003 population were applicable to the 2004
population used in this analysis. Thus, results from this
research could be used for economic evaluations using
our redeveloped stroke economic model [5]. Standard
population life expectancies were not used as they were
considered insufficient to address the impact on QoL,
since people with stroke may also have non stroke-related
disability as they get older.
Analysis
T-tests for continuous variables were applied using Inter-
cooled STATA version 8 (Stata Corporation, 2003). The
level of significance was set at p < 0.05 (two-sided).
W e used a 3% discount rate to accord with methods
recommended in the Australian BoD study [14]. Since the
issue of discounting QALYs is still debated [19], undis-
c o u n t e d  Q A L Y s  w e r e  a l s o  e s t i m a t e d .  W e  a l s o  p r o v i d e
estimates for different age groups and gender using a 5%
discount rate to accord with other studies. Multivariable
probabilistic uncertainty analyses were undertaken using
@Risk software version 4.5 (Palisade Corporation, 2005).
The sampling variations incorporated for point estimates
were based on triangular distributions (minimum, most
likely and maximum) that approximate a normal distribu-
tion. The minimum and maximum values were obtained
from literature reviews or best available data and applied
as a proportion greater or less than the point estimate.
Variables included incidence (range used -5% to +1%)
[20,21]; survival (-2% to +1%) [22,23]; and average QALYs
lost (ischemic stroke 4%; ICH 2% based on the plausible
variation found using NEMESIS data). Three thousand
'Monte Carlo' simulations were undertaken to ensure
convergence. Convergence was defined as less than 1.5%
variation in primary outcome statistics, such as numbers
of strokes. The 3,000 individually simulated point esti-
mates were used to estimate a mean, median and 95%
uncertainty interval for the results.
To test the sensitivity of the QALY loss estimates we
substituted the NEMESIS QoL weights and case fatality
rates with estimates used in the 2003 BoD study for
stroke. To distinguish between these estimates, we define
these results as DALYs. The results were compared to
describe the potential variation that might occur when
different input parameters (e.g. QoL weights and case-
fatality rates) for Australia are used.
Results
At 12 months and 5 years, 237 first-ever stroke survivors
provided AQoL responses. The sample size was insuffi-
cient to estimate utilities beyond age and gender catego-
ries. We found that the utilities obtained for males and
females were not statistically different (data not shown).
Thus, utility data were disaggregated by age band and the
net difference between published normal Australian pop-
ulation data [17] were then estimated (Table 1). In those
aged < 64 years, differences between the normal popula-
tion and NEMESIS survivors were small, and were similar
at 12 months and 5 years post stroke. This provides evi-
dence that disutility from stroke tends to stabilise after 12
months in people of working or younger ages. In contrast,
in those aged over 64 years, the net difference in utilities
between the normal population and NEMESIS survivors
was large at both 12 months and 5 years. In addition, the
health loss was greater at 5 years than at 12 months and
may be associated with survivors experiencing non-
stroke related disability.
The estimated 'lifetime' health loss attributable to first-ever 
strokes
Overall, the average QALYs lost per first-ever stroke case
weighted for age and gender distribution was estimated
to be 5.09 for ischemic stroke and 6.17 for ICH (Table 2).
This means that a person who has a stroke loses 5 or six
years of healthy life when compared to the normal popu-
lation. The equivalent undiscounted weighted average
QALYs lost were 7.24 for ischemic stroke and 8.88 forCadilhac et al. Health and Quality of Life Outcomes 2010, 8:49
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ICH. The effect of a 3% discount rate was to reduce aver-
age QALYs lost per case by about two years for ischemic
stroke and almost three years for ICH. The difference in
average QALYs lost per case was significantly greater for
ICH than ischemic stroke (p < 0.0001) and was signifi-
cantly greater for females than males for each stroke sub-
types (both p < 0.0001; Table 2).
Applying these data to the 2004 Australian population,
we estimated that there would be median 27,344 (95% UI
26,517, 27,831) first-ever ischemic strokes and median
4,247 (95% UI 4,121, 4,322) ICHs in Australia. The total
QALYs lost attributable to these strokes were 139,018
(95% UI 133,311, 144,574) for incident ischemic stroke
and 26,177 (95% UI 25,304, 26,867) for incident ICH
(Table 3).
Sensitivity analysis
When QoL weights and case fatality rates applied in the
2003 BoD study for stroke were substituted for those
used in the primary analysis we found the difference
between the two health loss measures (i.e. reported as
DALYs and QALYs for simplicity) per case ranged from
Table 1: Average and net difference in utility scores between Australian population and first-ever stroke survivors.
Normal population† NEMESIS utility scores* Net difference (QoL 
weights)
Age n Mean 
utility
n 12 
months
SD 5 years SD 12 
months
5 years
< 55 578 0.85 27 0.8249 0.2231 0.8189 0.1751 0.0251 0.0311
55-64 378 0.80 33 0.7422 0.2762 0.7553 0.2700 0.0578 0.0447
65-74 301 0.79 85 0.6035 0.2963 0.5485 0.3188 0.1865 0.2415
75-84 263 0.75 74 0.4986 0.3123 0.3722 0.3282 0.2514 0.3778
85+ 96 0.66 18 0.2341 0.2643 0.1465 0.2241 0.4259 0.5135
Total 1 616 237 0.1886‡ 0.2533‡
*Utility scores were obtained using the Assessment of Quality of Life (AQoL) instrument.
†Obtained from AQoL publication [17] and based on equivalent midpoint age used in the model. The normal population for age less than 55 
comprises estimates for the 30-39 age group. This is because the midpoint for NEMESIS cases in the < 55 age group was 33 years. Utility 
estimates in the other age bands result from normal population for ages 50-59, 60-69, 70-79 and 80+, respectively.
‡summary estimate weighted for age and population size
NEMESIS: North East Melbourne Stroke Incidence Study.
Table 2: Quality Adjusted Life Years lost according to stroke subtype and gender
Ischemic stroke Intracerebral Hemorrhage
Males
N= 14 139
Females
N= 13 521
Males
N = 2 087
Females
N = 2 204
QALY lost per case
Age Group years QALYs with 3% discounting (5% discounting, 0% discounting)
< 55 5.5 (3.7, 11.1) 9.8 (4.7, 20.2) 10.7 (7.3, 21.7) 12.5 (8.6, 25.6)
55-64 6.3 (5.0, 9.7) 7.6 (5.8, 12.1) 7.4 (5.9, 11.0) 10.9 (8.6, 16.3)
65-74 6.6 (5.7, 8.5) 7.6 (6.5, 10.2) 6.6 (5.7, 8.4) 7.6 (6.4, 10.1)
75-84 3.7 (3.3, 4.3) 4.9 (4.4, 5.9) 3.9 (3.5, 4.5) 5.1 (4.6, 6.1)
85+ 2.3 (2.1, 2.5) 2.5 (2.4, 2.8) 2.2 (2.1, 2.4) 2.4 (2.2, 2.6)
Weighted average 
(SD)†
4.69 (0.38) 5.51 (0.46)* 5.82 (0.67) 6.50 (0.40)*
Total weighted 
average (SD)†
5.09 (0.20) 6.17 (0.26)*
Undiscounted total 
weighted average
7.24 8.88
*p value < 0.0001; QALYs: Quality Adjusted Life Years; SD: standard deviation; †3% discount rate used.Cadilhac et al. Health and Quality of Life Outcomes 2010, 8:49
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about 0.28 (~3 months) for ICH and 0.40 (~5 months) for
ischemic stroke (Table 4). The greatest differences
between the two outcome measures were seen in those
aged less than 55-years where the DALY estimate was
larger (Figure 1). This difference was observed in both
stroke subtypes, among both males (2.3 years for ICH and
3 years for ischemic stroke) and females (1 year for ICH
and 1.3 years for ischemic stroke). Conversely, in the
older age bands (> 65 years) for males the QALYs lost
were slightly greater (approximately 4 months more) than
the DALYs.
Discussion
We found that people with ICH incurred greater health
losses over a lifetime than those having an ischemic
stroke and that this is explained by greater stroke-related
case fatality in cases with ICH (average over 5 years was
40% greater for ICH). Moreover, since ICH's experience
stroke a younger age, those that survive also have a
greater duration of disability since these survivors will
have a greater life expectancy. We also found that QALY
losses were greater for females than males in both stroke
subtypes. Previous research on QALYs lost from stroke
have been provided for generic stroke or by stroke sever-
ity [8,19]. It is reported that only about half of the vari-
ance in QoL is explained by stroke severity [13]. Because
the QoL weights used were the same for both stroke sub-
types and gender, the differences that we observed in
QALYs between the stroke types reflect differences in the
Table 3: Modelled estimates of stroke subtype and QALYs lost: Results of uncertainty analyses.
Modeled point estimates† 95% Uncertainty interval†
Stroke subtype Mean Median Lower bound (2.5%) Higher bound 
(97.5%)
Ischemic stroke
Number of strokes 27,291 27,344 26,517 27,831
Total number of 
QALYs lost 
(incident cases) *
138,962 139,018 133,311 144,574
Intracerebral 
Hemorrhage
Number of strokes 4,239 4,247 4,121 4,322
Total number of 
QALYs lost 
(incident cases)‡
26,145 26,177 25,304 26,867
QALYs: Quality Adjusted Life Years; *3% discount rate used; †3,000 simulations.
Table 4: Difference in DALYs and QALYs: Sensitivity analyses for average lifetime health loss*.
Stroke subtype DALYs QALYs Difference
Intracerebral hemorrhage 
(n = 4 291)
Average per first-ever 
stroke event
6.45 6.17 0.28
Total health loss for 
cohort
27 696 26 456 1 240
Ischemic stroke (n = 27 660)
Average per first-ever 
stroke event
5.49 5.09 0.40
Total health loss for 
cohort (years lost)
151 982 140 835 11 147
*Weighted by age and gender distribution of the 2004 reference cohort. DALYs estimated using the Western Australian ' excess' case fatality 
rate from the WA hospital morbidity database after 28 days following stroke and disability weights for stroke [14]. DALYs: Disability Adjusted 
Life Years; QALYs: Quality Adjusted Life Years.Cadilhac et al. Health and Quality of Life Outcomes 2010, 8:49
http://www.hqlo.com/content/8/1/49
Page 6 of 8
age of stroke onset and case fatality between these sub-
types.
There has been considerable discussion about the best
method for deriving the QoL weight. It is important that
this is measured carefully because it comprises a major
component of the QALY and inaccuracies will lead to
inaccurate estimates. The estimates of QoL weights
reported in the literature vary considerably for generic
stroke, ranging from 0.29 to 0.903 in a recent meta-analy-
sis [13]. These large differences have been attributed to
different elicitation methods [19] (e.g. from people with
and without stroke or health experts [8]) including the
type and range of tool used; timing of elicitation between
the event and the assessment; differences in age and gen-
der; and the variance for weights obtained [13]. In our
study, the QoL utility loss varied by age and time since
stroke and ranged between 0.025 and 0.514. Our sum-
mary QoL weight estimate at 12 months was 0.19 and at 5
years 0.25 (adjusted for age and population size). These
preference weights are consistent with the lower bound of
those reported in the literature.
There are a number of strengths in this study. First, we
used comprehensive data obtained from a large commu-
nity-based stroke incidence study (NEMESIS). Impor-
tantly, the QoL weights were directly elicited from the
same patients at 12 months and 5 years using the AQoL
instrument and are appropriate for the reference popula-
tion [16]. Use of QoL weights for survivors for up to 5
years is an added advantage to previous studies that have
been based on 12-month estimates [13]. This provides a
longer-term perspective rarely included in the estimation
of health loss for stroke. Furthermore, because health loss
was estimated separately for ICH and ischemic stroke,
this will enable investigators to evaluate interventions
specific to ICH and ischemic stroke.
Similar to other studies of this type, the generalisability
of the results may be limited. Although NEMESIS esti-
mates are unbiased at a community level as we have
obtained almost every case in a specific population (i.e.
community-based rather than hospital-based) and evi-
dence for the 2003 Australian BoD study provide good
evidence that these data are fairly representative for Aus-
Figure 1 Differences in average health loss (years) when using different case-fatality and preference disease weights for stroke, according 
to age group.
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tralia as a whole, potential differences across Australia in
ethnicity and socioeconomic status may be important.
Therefore, it was necessary to provide detailed sensitivity
and uncertainty analyses for these data which provide a
plausible range of variation for Australia. In countries
with demographic and life expectancy characteristics
comparable to Australia, our QoL weights should, there-
fore, be reasonably applicable.
Other limitations include the assumption that NEME-
SIS incidence rates are applicable for Australia; that use of
the normal population utility values to estimate pre-
stroke utility are applicable to people who experience
stroke when their risk profile may mean they have greater
pre-morbid disability; and longer-term (5 year) disutility
in people with stroke may reflect co-morbidity from
other diseases. Another important limitation was the
assumption that in those surviving beyond 5 years the
QoL weight values that were applied were those of the
next older age band. Because the available longitudinal
d a t a  r e  q u a l i t y  o f  l i f e  i n  t h e  l o n g - t e r m  a r e  l i m i t e d  i n
stroke cohorts we adopted this approach as the most fea-
sible. It also ensured that these data were consistent with
those of other studies. Methods used to address this limi-
tation included (1) describing the health loss for stroke
according to stroke subtype since this is one of the major
factors likely to influence health status over time; (2) use
of the 5 year QoL weight values; and (3) multivariable
probabilistic uncertainty analysis to assess the impact of a
range of important variables including survival rates
where evidence is limited but a plausible range of values
could be considered. Lastly, the use of triangular distribu-
tions rather than use of normal distributions for esti-
mates derived from NEMESIS, such as the QoL weight
may have underestimated the uncertainty. It was the con-
sidered view of the author group, that triangular distribu-
tions would enable ranges to be selected that would best
reflect the data we had, as samples size were small when
QoL data were disaggregated by the 5 age groups nomi-
nated.
These identified limitations may provide sources of
over and under estimation of health loss. Inaccurate esti-
mation of health-related QoL can have major implica-
tions when used to undertake cost-effectiveness analysis.
This is because, as a summary measure for population
health which attributes a perceived social value to differ-
ent health states, variance in QALYs may result in inap-
propriate resource allocation decisions [19]. In other
words, use of different QoL weights may over- or under-
estimate the QALY gain for an intervention therefore
producing contradictory cost-effectiveness results. Use of
multivariable probabilistic uncertainty and sensitivity
analyses in this study were used to address such potential
limitations and, overall, the estimates were fairly robust.
Conclusions
Estimates of health loss measured as QALYs were pre-
sented for Australia. Notably, these estimates were based
on patient-level data obtained up to 5 years following
stroke. We provide evidence that the health loss attribut-
able to ICH and ischemic stroke are different; health loss
also varies between males and females. Therefore, when
undertaking studies of disease burden in stroke, investi-
gators should account for these differences between sub-
type and gender. Otherwise, in countries where ICH is
more common, the disease burden for stroke may be
underestimated. Lastly, the estimates provide quantifiable
measures of the average health loss over a lifetime per
first-ever case of stroke that may be applied in economic
evaluations to determine the cost-effectiveness of preven-
tion interventions.
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